BioSpace News Archive

Geneyx Genomex Ltd (Geneyx), an Israel-based developer of a genetic data analysis and interpretation platform, announced today that it has closed its seed round financing led by Capri Ventures and Accenture Ventures to help the company expand its global footprint and accelerate the development of its technology.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its financial results for the third quarter ended September 30, 2021 and provided updated 2021 guidance.

Athenex today announced a licensing agreement with the National Cancer Institute (NCI), an institute of the National Institutes of Health (NIH), to expand the development of T cell receptor (TCR) based allogeneic natural killer T (NKT) cell

Neoleukin Therapeutics, Inc., today announced that management will participate in two upcoming investor conferences. Presentation Details: Event: Stifel 2021 Virtual Healthcare Conference Date: Tuesday, November 16, 2021 Time: 3:20 to 3:50 p.m. EST

Kane Biotech Inc. will announce its third quarter 2021 financial results after market close on Thursday, November 16, 2021.

Avadel Pharmaceuticals plc announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences in November: Stifel’s 2021 Virtual Healthcare Conference: Fireside chat on Tuesday, November 16 at 8:00 a.m. E.T.

Aravive, Inc. today announced that positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept

Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Terrence Fisher, Ph.D., Vice President, Clinical Science, is scheduled to present at the Clinical Trials on Alzheimer’s Disease Meeting in Boston, Massachusetts on Thursday, November 11, 2021.

MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it will present new data from three poster presentations at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

Pasithea Therapeutics Corp. today announced the formation of its Scientific Advisory Board (“SAB”) to be chaired by esteemed psychiatrist, Charles Nemeroff, M.D., Ph.D.